Cargando…

MCM4 Is a Novel Biomarker Associated With Genomic Instability, BRCAness Phenotype, and Therapeutic Potentials in Soft-Tissue Sarcoma

Soft-tissue sarcoma (STS) is represented by a heterogeneous group of rare malignancies with various molecular oncogenesis. Therapies targeting DNA repair pathways in STS have achieved minimal progress, potentially due to the lack of molecular biomarker(s) beyond the histology subtype. In this report...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qi, Bao, Qiyuan, Xu, Yiqi, Fu, Yucheng, Jin, Zhijian, Wang, Jun, Zhang, Weibin, Shen, Yuhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222794/
https://www.ncbi.nlm.nih.gov/pubmed/34178990
http://dx.doi.org/10.3389/fcell.2021.666376
_version_ 1783711563618713600
author Liu, Qi
Bao, Qiyuan
Xu, Yiqi
Fu, Yucheng
Jin, Zhijian
Wang, Jun
Zhang, Weibin
Shen, Yuhui
author_facet Liu, Qi
Bao, Qiyuan
Xu, Yiqi
Fu, Yucheng
Jin, Zhijian
Wang, Jun
Zhang, Weibin
Shen, Yuhui
author_sort Liu, Qi
collection PubMed
description Soft-tissue sarcoma (STS) is represented by a heterogeneous group of rare malignancies with various molecular oncogenesis. Therapies targeting DNA repair pathways in STS have achieved minimal progress, potentially due to the lack of molecular biomarker(s) beyond the histology subtype. In this report, we comprehensively analyzed the expression profiles of 100 liposarcomas (LPSs), the most common STS subtype, in comparison with 21 adipose tissues from multiple GEO datasets to identify the potential prognostic and therapeutic biomarker for LPS. Furthermore, we investigated TCGA database, our archived tumor samples, and patient-derived tumor cell cultures (PTCCs) as a validation. We identified a total of 69 common differentially expressed genes (DEGs) among public datasets, with mini-chromosome maintenance protein 4 (MCM4) identified as a novel biomarker correlated with patients’ clinical staging and survival outcome. MCM4-high expression LPS was characterized by MCM4 copy number increase, genomic instability, and BRCAness phenotype compared with the MCM4-low expression counterpart. In contrast, the mutational and the immune landscape were minimally different between the two groups. Interestingly, the association of MCM4-high expression with genomic instability and BRCAness were not only validated in LPS samples from our institution (n = 66) but also could be expanded to the pan-sarcoma cohort from TCGA database (n = 263). Surprisingly, based on four sarcoma cell lines and eight PTCCs (three LPS and five other sarcoma), we demonstrated that MCM4 overexpression tumors were therapeutically sensitive to PARP inhibitor (PARPi) and platinum chemotherapy, independent of the histology subtypes. Our study, for the first time, suggested that MCM4 might be a novel prognostic biomarker, associated with dysregulated DNA repair pathways and potential therapeutic vulnerability in STS.
format Online
Article
Text
id pubmed-8222794
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82227942021-06-25 MCM4 Is a Novel Biomarker Associated With Genomic Instability, BRCAness Phenotype, and Therapeutic Potentials in Soft-Tissue Sarcoma Liu, Qi Bao, Qiyuan Xu, Yiqi Fu, Yucheng Jin, Zhijian Wang, Jun Zhang, Weibin Shen, Yuhui Front Cell Dev Biol Cell and Developmental Biology Soft-tissue sarcoma (STS) is represented by a heterogeneous group of rare malignancies with various molecular oncogenesis. Therapies targeting DNA repair pathways in STS have achieved minimal progress, potentially due to the lack of molecular biomarker(s) beyond the histology subtype. In this report, we comprehensively analyzed the expression profiles of 100 liposarcomas (LPSs), the most common STS subtype, in comparison with 21 adipose tissues from multiple GEO datasets to identify the potential prognostic and therapeutic biomarker for LPS. Furthermore, we investigated TCGA database, our archived tumor samples, and patient-derived tumor cell cultures (PTCCs) as a validation. We identified a total of 69 common differentially expressed genes (DEGs) among public datasets, with mini-chromosome maintenance protein 4 (MCM4) identified as a novel biomarker correlated with patients’ clinical staging and survival outcome. MCM4-high expression LPS was characterized by MCM4 copy number increase, genomic instability, and BRCAness phenotype compared with the MCM4-low expression counterpart. In contrast, the mutational and the immune landscape were minimally different between the two groups. Interestingly, the association of MCM4-high expression with genomic instability and BRCAness were not only validated in LPS samples from our institution (n = 66) but also could be expanded to the pan-sarcoma cohort from TCGA database (n = 263). Surprisingly, based on four sarcoma cell lines and eight PTCCs (three LPS and five other sarcoma), we demonstrated that MCM4 overexpression tumors were therapeutically sensitive to PARP inhibitor (PARPi) and platinum chemotherapy, independent of the histology subtypes. Our study, for the first time, suggested that MCM4 might be a novel prognostic biomarker, associated with dysregulated DNA repair pathways and potential therapeutic vulnerability in STS. Frontiers Media S.A. 2021-06-10 /pmc/articles/PMC8222794/ /pubmed/34178990 http://dx.doi.org/10.3389/fcell.2021.666376 Text en Copyright © 2021 Liu, Bao, Xu, Fu, Jin, Wang, Zhang and Shen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Liu, Qi
Bao, Qiyuan
Xu, Yiqi
Fu, Yucheng
Jin, Zhijian
Wang, Jun
Zhang, Weibin
Shen, Yuhui
MCM4 Is a Novel Biomarker Associated With Genomic Instability, BRCAness Phenotype, and Therapeutic Potentials in Soft-Tissue Sarcoma
title MCM4 Is a Novel Biomarker Associated With Genomic Instability, BRCAness Phenotype, and Therapeutic Potentials in Soft-Tissue Sarcoma
title_full MCM4 Is a Novel Biomarker Associated With Genomic Instability, BRCAness Phenotype, and Therapeutic Potentials in Soft-Tissue Sarcoma
title_fullStr MCM4 Is a Novel Biomarker Associated With Genomic Instability, BRCAness Phenotype, and Therapeutic Potentials in Soft-Tissue Sarcoma
title_full_unstemmed MCM4 Is a Novel Biomarker Associated With Genomic Instability, BRCAness Phenotype, and Therapeutic Potentials in Soft-Tissue Sarcoma
title_short MCM4 Is a Novel Biomarker Associated With Genomic Instability, BRCAness Phenotype, and Therapeutic Potentials in Soft-Tissue Sarcoma
title_sort mcm4 is a novel biomarker associated with genomic instability, brcaness phenotype, and therapeutic potentials in soft-tissue sarcoma
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222794/
https://www.ncbi.nlm.nih.gov/pubmed/34178990
http://dx.doi.org/10.3389/fcell.2021.666376
work_keys_str_mv AT liuqi mcm4isanovelbiomarkerassociatedwithgenomicinstabilitybrcanessphenotypeandtherapeuticpotentialsinsofttissuesarcoma
AT baoqiyuan mcm4isanovelbiomarkerassociatedwithgenomicinstabilitybrcanessphenotypeandtherapeuticpotentialsinsofttissuesarcoma
AT xuyiqi mcm4isanovelbiomarkerassociatedwithgenomicinstabilitybrcanessphenotypeandtherapeuticpotentialsinsofttissuesarcoma
AT fuyucheng mcm4isanovelbiomarkerassociatedwithgenomicinstabilitybrcanessphenotypeandtherapeuticpotentialsinsofttissuesarcoma
AT jinzhijian mcm4isanovelbiomarkerassociatedwithgenomicinstabilitybrcanessphenotypeandtherapeuticpotentialsinsofttissuesarcoma
AT wangjun mcm4isanovelbiomarkerassociatedwithgenomicinstabilitybrcanessphenotypeandtherapeuticpotentialsinsofttissuesarcoma
AT zhangweibin mcm4isanovelbiomarkerassociatedwithgenomicinstabilitybrcanessphenotypeandtherapeuticpotentialsinsofttissuesarcoma
AT shenyuhui mcm4isanovelbiomarkerassociatedwithgenomicinstabilitybrcanessphenotypeandtherapeuticpotentialsinsofttissuesarcoma